NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General Board of Community Health Councils in Wales British National Formulary Care Quality Commission Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland Hafal Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency MIND Cymru National Association of Primary Care National Mental Health Development Unit National Pharmacy Association NHS Alliance NHS Commercial Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium Possible comparator manufacturers Actavis UK (risperidone, olanzapine) Dexcel Pharma (risperidone) Eli Lilly (olanzapine) Genus Pharmaceuticals (lorazepam) Goldshield Pharmaceuticals (haloperidol) Janssen (haloperidol, risperidone) Otsuka and Bristol-Myers Squibb
WISH – A voice for women's mental health	(aripiprazole)Pfizer (lorazepam, risperidone)

National Institute for Health and Clinical Excellence

Final matrix for the technology appraisal of loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder

Issue date: January 2013 Page 1 of 4

Consultees Commentators (no right to submit or appeal) Professional groups Rosemont Pharmaceuticals British Association for Counselling and (haloperidol) **Psychotherapy** Sandoz (olanzapine, risperidone) British Association for Zentiva UK (olanzapine) Psychopharmacology British Association for Services to the Relevant research groups Elderly Cochrane Depression, Anxiety & British Association of Behavioural and **Neurosis Group** Cognitive Psychotherapies Cochrane Schizophrenia Group British Association of Institute of Psychiatry **Psychotherapists** MRC Clinical Trials Unit British Geriatrics Society National Institute for Health Research **British Neuropsychiatry Association** National Primary Care Research & British Psychoanalytic Council **Development Centre** British Psychological Society Research Institute for the Care of Older College of Mental Health Pharmacy People Counsellors and Psychotherapists in **Evidence Review Group Primary Care** Evidence Review Group tbc Mental Health Nurses Association National Institute for Health Research **National Pharmacy Association** Health Technology Assessment Primary Care Mental Health Education Programme Royal College of General Practitioners Royal College of Nursing Associated Guideline groups Royal College of Pathologists National Collaborating Centre for Royal College of Physicians Mental Health Royal College of Psychiatrists Royal Pharmaceutical Society Associated Public Health groups Royal Society of Medicine None United Kingdom Clinical Pharmacy Association • United Kingdom Council for Psychotherapy Others Aneurin Bevan Health Board Department of Health Inner North East London PCT Cluster Welsh Government

Issue date: January 2013 Page 2 of 4

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Clinical Excellence

Final matrix for the technology appraisal of loxapine inhalation for the treatment of acute agitation and disturbed behaviours associated with schizophrenia or bipolar disorder

Issue date: January 2013 Page 3 of 4